A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohns Disease

Phase 2

• Conditions: Health Condition 1: null- Crohnâ??s disease.

• Registration Number: CTRI/2013/09/003992
• Lead Sponsor: Pfizer Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 275

Inclusion Criteria

•Subjects who complete 26-week maintenance treatment of the A3921084 study or subjects who withdraw early due to A3921084 study treatment failure (see Appendix 5).

•Women of childbearing potential must test negative for pregnancy prior to study enrolment.

•Sexually active females of childbearing potential are required to use adequate

Exclusion Criteria

•Subjects who have been discontinued due to protocol violation(s) (as determined by the Sponsor) in the A3921084 study.

•Subjects who were discontinued from the A3921084 study due to an adverse event.

•Subjects likely to require any non-elective surgery or surgery requiring overnight stay (with the exception of minor same day outpatient procedures that will not interfere with study drug dosing).

Study & Design

• Study Type: Interventional
• Study Design: Not specified